BBIO(BBIO)
BBIO
Q4 2026 EPS Estimate
$-0.67
Oct 28, 2026 · Reports after close
Revenue Estimate
$267M
FY2027E EPS$0.05
FY2028E EPS$3.58
Analyst Sentiment
Wall St. Consensus
Buy27 analysts·High coverage
72
Score
24 Buy (89%)3 Hold (11%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
2489%
Hold
311%
Sell
00%
Strong Sell
00%
Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.
Price Target Expectations
Bear
$96.00
+22.0%
Consensus
$106.50
+35.3%
Bull
$130.00
+65.2%
12-Month Target Range27 analysts
$96.00$106.50$130.00
Current $78.69Consensus
Current Price
$78.69
Upside to Consensus
$27.81
Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.
Earnings & Revenue Estimates
Forward Growth Estimates (YoY)
FY2027
Rev+66.14%
EPS—
FY2028
Rev+52.69%
EPS+7032.14%
FY2029
Rev+43.24%
EPS+112.31%
Raw consensus estimates (low / average / high) from covering analysts.
Annual
| Metric | FY2026E | FY2027E | FY2028E | FY2029E | FY2030E |
|---|---|---|---|---|---|
| Revenue Avg | $1.01B | $1.68B | $2.56B | $3.67B | $4.64B |
| Low | $965M | $1.50B | $2.28B | $3.32B | $4.19B |
| High | $1.10B | $1.87B | $3.10B | $4.20B | $5.31B |
| EBITDA Avg | $-1.01B | $-1.68B | $-2.56B | $-3.67B | $-4.64B |
| Low | $-1.10B | $-1.87B | $-3.10B | $-4.20B | $-5.31B |
| High | $-965M | $-1.50B | $-2.28B | $-3.32B | $-4.19B |
| EBIT Avg | $-1.01B | $-1.68B | $-2.56B | $-3.67B | $-4.64B |
| Low | $-1.10B | $-1.87B | $-3.10B | $-4.20B | $-5.31B |
| High | $-965M | $-1.50B | $-2.28B | $-3.32B | $-4.19B |
| Net Income Avg | $-525M | $33M | $739M | $1.50B | $2.02B |
| Low | $-678M | $-72M | $109M | $1.31B | $1.76B |
| High | $-302M | $62M | $1.41B | $1.78B | $2.40B |
| EPS Avg | $-2.67 | $0.05 | $3.58 | $7.59 | $10.22 |
| Low | $-3.44 | $-0.37 | $0.55 | $6.64 | $8.94 |
| High | $-1.53 | $0.31 | $7.14 | $9.02 | $12.15 |
| Analysts (Rev / EPS) | 15 / 12 | 14 / 12 | 16 / 14 | 14 / 7 | 14 / 11 |
Quarterly
| Metric | Q3 2026 | Q4 2026 | Q1 2027 | Q2 2027 | Q3 2027 | Q4 2027 | Q1 2028 | Q2 2028 |
|---|---|---|---|---|---|---|---|---|
| Revenue Avg | $267M | $309M | $328M | $377M | $429M | $511M | $525M | $585M |
| Low | $247M | $268M | $296M | $340M | $387M | $461M | $474M | $528M |
| High | $279M | $378M | $377M | $433M | $493M | $587M | $603M | $672M |
| EBITDA Avg | $-267M | $-309M | $-328M | $-377M | $-429M | $-511M | $-525M | $-585M |
| Low | $-279M | $-378M | $-377M | $-433M | $-493M | $-587M | $-603M | $-672M |
| High | $-247M | $-268M | $-296M | $-340M | $-387M | $-461M | $-474M | $-528M |
| EBIT Avg | $-267M | $-309M | $-328M | $-377M | $-429M | $-511M | $-525M | $-585M |
| Low | $-279M | $-378M | $-377M | $-433M | $-493M | $-587M | $-603M | $-672M |
| High | $-247M | $-268M | $-296M | $-340M | $-387M | $-461M | $-474M | $-528M |
| Net Income Avg | $-122M | $-91M | $-51M | $-34M | $8M | $72M | $105M | $161M |
| Low | $-163M | $-164M | $-60M | $-40M | $7M | $63M | $92M | $141M |
| High | $-69M | $27M | $-44M | $-29M | $10M | $86M | $125M | $192M |
| EPS Avg | $-0.62 | $-0.46 | $-0.26 | $-0.17 | $0.04 | $0.37 | $0.54 | $0.82 |
| Low | $-0.83 | $-0.84 | $-0.31 | $-0.20 | $0.04 | $0.32 | $0.47 | $0.72 |
| High | $-0.35 | $0.14 | $-0.23 | $-0.15 | $0.05 | $0.44 | $0.64 | $0.98 |
| Analysts (Rev / EPS) | 9 / 6 | 11 / 6 | 5 / 2 | 5 / 2 | 8 / 2 | 5 / 2 | 4 / 5 | 5 / 5 |